From the News page: a new NIPS provider, and financial news about two others.
Quest enters NIPS market
Quest Diagnostics was once a partner lab for Natera’s Panorama, then Sequenom’s MaterniT21, and now it has developed its own test based in part on Sequenom’s technology.
The new test is called QNatal Advanced. Some fact checking from the Press Release:
- “QNatal Advanced analyzes cell-free fetal DNA in circulating maternal blood” **ahem**no it doesn’t. It’s placental DNA, not fetal.
- “The phrase ‘noninvasive prenatal screening’ coined by Quest Diagnostics reflects the seriousness with which we take our responsibility to ensure women have access to health insights that are appropriate, actionable and of the highest quality,” said Douglas S. Rabin, MD, medical director, women’s health, Quest Diagnostics. **cough** no Quest didn’t “coin” noninvasive prenatal screening–ACMG did (and had Quest read ACMG’s statement it would have also seen it’s placental DNA, not fetal).
That said, Quest should be commended as it is recommending that its new test be restricted to “high risk” patients and is emphasizing that its test is a screening test, not a diagnostic test.
Sequenom’s stock price drops 15% in one day
So says the report from GenomeWeb:
mixed first quarter financial results led to a sell-off of Sequenom shares, which were down 25 percent in May compared to April. The day after it announced its results, its stock price dropped 15 percent.
Natera issues IPO seeking $100 million
Interesting report (again from GenomeWeb):
- Natera issued an IPO seeking $100 million
- Natera had previously raise $55 million in private financing
- Natera performed 180,000 Panorama tests in 2014 alone–that’s almost 500 tests every. single. day.